Result:Weak· Market: Up#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 0.67 | 7.6% | |
| Total Income | 0.67 | 7.6% | |
| Expenditure | 0.79 | 0.6% | 2128.8% |
| PBT | -0.12 | 99.2% | 240.4% |
| Net Profit | -0.12 | 99.2% | 240.4% |
| OPM | -18.03% | 9.67pp | |
| NPM | -18.03% | 9.67pp | |
| EPS | 0.20 | 100.0% |
Pharma small-cap loss deepens sequentially on a still-near-zero revenue base, so despite the huge YoY% swing off a negligible prior-year base it remains a clear loss with no core-business turnaround.
Informational and educational content only. Not investment advice.